As of November 10, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Cellectis S.A. The largest reported stake is Bpifrance Participations S.A.'s, at 10%. 2 filings are on record since December 12, 2025 (Schedule 13D/A, November 9, 2026).
Sell to companies like Cellectis S.A? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Cellectis S.A. has 2 Schedule 13D or 13G filings on record since 2025-12-12. 1 holder's latest filing reports 5% or more of ordinary shares, nominal value eur0.05 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Bpifrance Participations S.A. | 10% | 9,559,534 | SCHEDULE 13D/A, 2026-11-09 | 2026-10-28 |
Holding shares or following this stake? See who's behind Cellectis S.A. and the warning signs.
Free to see. No signup.
Keep reading
More on Cellectis S.A. and the records around it.
Companies that share a holder
- Bpifrance Participations S.A. also filed stake reports on 4 other companies: Pasqal Holding SA (Sep 2026), Constellium SE (May 2026), Valneva SE (May 2026)
Watch Cellectis S.A.
Get an email when Cellectis S.A. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cellectis S.A.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cellectis S.A.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cellectis S.A. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Bpifrance Participations S.A. | 0 | 9,559,534 | 0 | 5,873,247 | SCHEDULE 13D/A, 2026-11-09 |
| Caisse des Depots | 0 | 9,559,534 | 0 | 5,873,247 | SCHEDULE 13D/A, 2026-11-09 |
| CDC Croissance S.A. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-11-09 |
| EPIC Bpifrance | 0 | 9,559,534 | 0 | 5,873,247 | SCHEDULE 13D/A, 2026-11-09 |
| Bpifrance S.A. | 0 | 9,559,534 | 0 | 5,873,247 | SCHEDULE 13D/A, 2026-11-09 |
The latest filing identifies Cellectis S.A. by CUSIP 15117K103 and gives its principal executive office as 8, rue de la Croix Jarry, Paris (SCHEDULE 13D/A, 2026-11-09).
Purpose of Transaction (Item 4)
Bpifrance Participations S.A.
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: CDC Croissance sold the amount of Ordinary Shares on the dates and at the prices set forth below in open market transactions. All daily sales of the Ordinary Shares were sold in multiple transactions at varying prices. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this Schedule 13D. September 15, 2026: -284,444 Ordinary Shares at a weighted average price of EUR1.36 per share (multiple transactions at prices ranging from EUR1.30 to EUR1.45, inclusive). September 16, 2026: -70,671 Ordinary Shares at a weighted average price of EUR1.19 per share (multiple transactions at prices ranging from EUR1.17 to EUR1.30, inclusive). September 17, 2026: -94,885 Ordinary Shares at a weighted average price of EUR1.23 per share (multiple transactions at prices ranging from EUR1.15 to EUR1.29, inclusive). October 19, 2026: -111,425 Ordinary Shares at a weighted average price of EUR0.96 per share (multiple transactions at prices ranging from EUR0.94 to EUR1.01, inclusive). October 20, 2026: -158,575 Ordinary Shares at a weighted average price of EUR0.93 per share (multiple transactions at prices ranging from EUR0.91 to EUR0.96, inclusive). October 26, 2026: -31,734 Ordinary Shares at a weighted …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-11-09; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-12 | Bpifrance Participations S.A. | 11.1% | SCHEDULE 13D/A |
| 2026-11-09 | Bpifrance Participations S.A. | 10% | SCHEDULE 13D/A |
Questions about who owns Cellectis S.A.
Who owns Cellectis S.A.?
On this page, one holder's latest ownership filing reports 5% or more of Cellectis S.A.: Bpifrance Participations S.A. (10%, Schedule 13D/A, filed 2026-11-09).
When did Bpifrance Participations S.A. buy into Cellectis S.A.?
The filings give report dates, not purchase dates. The earliest filing from Bpifrance Participations S.A. on this page is the Schedule 13D/A, filed 2025-12-12, reporting 11.1%; its latest, Schedule 13D/A filed 2026-11-09, reports 10%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Cellectis S.A.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.